MedTrace Logo

Comparison of 1 Month vs. 12 Months DAPT in Patients Undergoing PCI With Genoss® DES

NCT05770674 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2186

Last updated 2023-03-15

No results posted yet for this study

Summary

This study is a prospective, open-label, multicenter, randomized clinical trial to evaluate the efficacy of 1 month dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel followed by clopidogrel monotherapy, compared with 12 months DAPT with aspirin plus clopidogrel in patients undergoing percutaneous coronary intervention with Genoss® drug eluting stents.

Conditions

Interventions

DRUG

1 Month vs. 12 Months DAPT

Dual antiplatelet therapy with aspirin plus clopidogrel will be given for the following period after PCI according to patient allocation 1. 1 Month following PCI, followed by clopidogrel monotherapy 2. 12 Months following PCI

Sponsors & Collaborators

  • Uijeongbu St. Mary Hospital

    collaborator OTHER

  • St Vincent's Hospital

    collaborator OTHER

  • Bucheon St. Mary's Hospital

    collaborator OTHER

  • Wonju Severance Christian Hospital

    collaborator OTHER

  • Chungbuk National University Hospital

    collaborator OTHER

  • Daejeon St. Mary's hospital

    collaborator OTHER

  • Korea University Guro Hospital

    collaborator OTHER

  • Seoul St. Mary's Hospital

    collaborator OTHER

  • Kiyuk Chang

    lead OTHER

Principal Investigators

  • Kiyuk Chang · Seoul St. Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2023-12-31
Completion
2025-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05770674 on ClinicalTrials.gov